Brian Elliott, Executive Director International MeTA Secretariat 19 th May 2009 Medicines Transparency Alliance (MeTA) Overview and lessons learned in pilot countries MeTA 08/04/2009

MeTA Principles Commitment to improving health Comprehensive approach to health systems, including pharmaceuticals Transparency and accountability can: Improve system performance Build confidence Support equity and social justice Multi-stakeholder approach needed

Commitment to improving health

Comprehensive approach to health systems, including pharmaceuticals

Transparency and accountability can:

Improve system performance

Build confidence

Support equity and social justice

Multi-stakeholder approach needed

MeTa Country commitments Establish an effective multi-stakeholder forum Progressive disclosure of data in four areas Quality Regulatory, sourcing, quality assurance, vigilance Availability Supply chain operations, equitable access Price Supplier, wholesaler, retailer, import taxes, duties, affordability Promotion Objective information, rational use, ethical advertising and promotion

Establish an effective multi-stakeholder forum

Progressive disclosure of data in four areas

Quality Regulatory, sourcing, quality assurance, vigilance

Availability Supply chain operations, equitable access

Price Supplier, wholesaler, retailer, import taxes, duties, affordability

Promotion Objective information, rational use, ethical advertising and promotion

MeTA Pilot Countries

MeTA Pilot objectives Add value to country ATM efforts through transparency and multi-stakeholder working Road test the MeTA approach in different country settings Engage stakeholders at country and int’l levels Provide a model for eventual roll out in further countries

Add value to country ATM efforts through transparency and multi-stakeholder working

Road test the MeTA approach in different country settings

Engage stakeholders at country and int’l levels

Provide a model for eventual roll out in further countries

MeTA implementation process Stakeholders engaged MeTA Council formed MeTA Secretariat formed Pre-MoU work done MoU signed Work started GHANA JORDAN KYRGYZSTAN PERU PHILIPPINES UGANDA ZAMBIA

Specific Success or Milestone GHANA JORDAN KYRGYZSTAN PERU PHILIPPINES UGANDA ZAMBIA Establishment of the physical secretariat Full support of government and private sector Identifying the stakeholders and approval of the work plan Sign MoU because it is final point Successful forums and especially the CSO Forum in Jan 2009 Successful launch and the receiving of funds Successful launch and media interest

Key Challenges to MeTA implementation Stakeholder engagement and maintaining interest Insufficient legislation/regulation and excessive bureaucracy Difficulties in extracting information Lack of tools for accessing information 19 05 /2009 MeTA

Stakeholder engagement and maintaining interest

Insufficient legislation/regulation and excessive bureaucracy

Difficulties in extracting information

Lack of tools for accessing information

Lessons learned in countries Country contexts are varied. MeTA needs to be country-led to succeed, so local conditions determine the timetable of the workplan and roll-out. It takes time to get the right people at the table and develop a working relationship between stakeholders with varied and sometimes conflicting interests. Consensus builds with a constant exchange of views. Commitment of the stakeholders is key to a successful process. Building trust is an essential part of the initiative. Some problems in the medicines supply chain require tough political action to solve. Starting work on less controversial issues is key. Systems and structures for disclosing data often do not exist in countries and may have to be created.

Country contexts are varied. MeTA needs to be country-led to succeed, so local conditions determine the timetable of the workplan and roll-out.

It takes time to get the right people at the table and develop a working relationship between stakeholders with varied and sometimes conflicting interests.

Consensus builds with a constant exchange of views.

Commitment of the stakeholders is key to a successful process.

Building trust is an essential part of the initiative.

Some problems in the medicines supply chain require tough political action to solve. Starting work on less controversial issues is key.

Systems and structures for disclosing data often do not exist in countries and may have to be created.

Key priorities for MeTA Progressive disclosure of data about medicines Developing and testing a new multi-stakeholder approach including identifying and trying to fill gaps in the MeTA Councils; preparing stakeholders for meaningful engagement Ensuring the strong engagement of the private sector at country and international level Increasing the voice of patients and consumers which involves strengthening capacity and opportunity for their engagement Documenting innovation, change and good practice across the programme.

Progressive disclosure of data about medicines

Developing and testing a new multi-stakeholder approach including identifying and trying to fill gaps in the MeTA Councils; preparing stakeholders for meaningful engagement

Ensuring the strong engagement of the private sector at country and international level

Increasing the voice of patients and consumers which involves strengthening capacity and opportunity for their engagement

Documenting innovation, change and good practice across the programme.

Congratulations to Jordan on the successful establishment of MeTA and every good wish for the success of the programme. International Secretariat, [email_address] www.MedicinesTransparency.org 10/06/09 MeTA

Congratulations to Jordan on the successful establishment of MeTA and every good wish for the success of the programme.

International Secretariat, [email_address]

www.MedicinesTransparency.org